| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5928607 | American Heart Journal | 2013 | 13 Pages |
Abstract
LEADER commenced in September 2010, and enrollment concluded in April 2012. There were 9,340 patients enrolled at 410 sites in 32 countries. The mean age of patients was 64.3 ± 7.2 years, 64.3% were men, and mean body mass index was 32.5 ± 6.3 kg/m2. There were 7,592 (81.3%) patients with prior CVD and 1,748 (18.7%) who were high risk but without prior CVD. It is expected that LEADER will provide conclusive data regarding the cardiovascular safety of liraglutide relative to the current standard of usual care for a global population of patients with T2DM.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Steven P. MD, Neil R. FRCP, Steven E. MD, Michael A. MD, Bernard MD, Gilbert H. MD, Stuart PhD, William M. MD, Richard M. MD, Johannes F.E. MD, Lasse Steen MD, PhD, Kirstine Brown MD, Alan C. MD, John B. MD, PhD,